UNSPSC 51323007: Levocarnitine propionate hydrochloride

This classification denotes a nutritional supplement C10H20NO4.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12FW2YBF04, chemically known as (2r)-3-carboxy-n,n,n-trimethyl-2-(propanoyloxy)propan-1-aminium chloride, but more generally known as levocarnitine propionate hydrochloride, which bears US NIH Compound Identifier 157836. European Medicines Agency schedules Levocarnitine propionate hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB36026.

Most nations, for tariff and trade purposes, schedule levocarnitine propionate hydrochloride under HS 29239000 and SITC 51481. As of Q4 2014, LEVOCARNITINE PROPIONATE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)O[C@H](CC(=O)O)C[N+](C)(C)C.[CL-].

UNSPSC 51323007 Levocarnitine propionate hydrochloride (Commodity) encompasses specialized pharmaceutical products that state and local governments procure for emergency medical services, pharmacy benefit programs, and health agency operations. Recent solicitations show state and local buyers sourcing advanced life support medications, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription fulfillment capabilities. The City of Tampa's Fire Rescue department, the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving state and local facilities across multiple states, and the Texas Health and Human Services Commission represent the kinds of issuing bodies active under this code — municipal emergency services, state health agencies, and multi-jurisdictional cooperative purchasing vehicles. Work solicited includes sealed bids for individual medication line items with strict expiration-date and delivery requirements, RFPs for large-scale pharmaceutical supply contracts through authorized wholesalers with competitive pricing models, and RFIs exploring direct-to-manufacturer contracting pathways outside traditional pharmacy benefit manager intermediaries.

Recent activity concentrates in Florida, Minnesota, Texas, and Oregon, with the most recent opportunity being the City of Tampa's April 2026 IFB for Advanced Life Support Medications (Bid No. 26-P-00188, response due April 8, 2026, estimated contract value $40,000.00) seeking four specific medication line items with nine-month minimum expiration dates and one-year initial term plus renewal options. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and 25 percent on compliance, pricing format capability, and administrative requirements. The Texas HHS Commission posted an RFI (HHS0017013, April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state intent to develop direct contracting models outside traditional GPO and PBM channels. Vendors pursuing opportunities under this code encounter cooperative purchasing vehicles, multi-state procurement, requirements for manufacturer certifications and supply-chain compliance documentation, and competitive pricing pressure across large-volume state and local health agency contracts.